Vaxcyte (PCVX) is a publicly traded Healthcare sector company. As of November 4, 2026, PCVX trades at $65.68 with a market cap of $9.57B and a P/E ratio of -17.32. PCVX moved +8.02% today. Year to date, PCVX is +42.55%; over the trailing twelve months it is +58.68%. Its 52-week range spans $27.66 to $90.75. Analyst consensus is strong buy with an average price target of $120.44. Rallies surfaces PCVX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Vaxcyte Q3 2026 net loss widens 40% to $297.1 million: Vaxcyte’s third-quarter net loss widened 40% year over year to $297.1 million, while research and development expenses rose 29% to $270.3 million. VAX-31 met all prespecified primary endpoints in the OPUS-1 adult trial, and the company had $2.26 billion in cash, cash equivalents and investments at September 30, excluding about $1.1 billion raised through October offerings.
| Metric | Value |
|---|---|
| Price | $65.68 |
| Market Cap | $9.57B |
| P/E Ratio | -17.32 |
| EPS | $-3.80 |
| Dividend Yield | 0.00% |
| 52-Week High | $90.75 |
| 52-Week Low | $27.66 |
| Volume | 1.87M |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-463.93M |
| Gross Margin | 0.00% |
9 analysts cover PCVX: 0 strong buy, 8 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $120.44.